Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
HKSE · HKD · Healthcare · Drug Manufacturers - Specialty & Generic
HK$0.097 (+6.59%) as of
Key statistics
- Market cap
- 162.77M
- EPS (TTM)
- -0.040
- Dividend yield
- 0.00%
- 52-week range
- 0.086 – 0.177
- Beta
- -0.08
- Revenue (TTM)
- 912.25M
- Profit margin
- -5.78%
- Volume
- 220.00k
About Shenzhen Neptunus Interlong Bio-technique Company Limited
Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, and selling of medicines and medical devices in the People's Republic of China. It operates through two segments, Manufacturing and Selling of medicines and medical devices; and Sales and Distribution of medicines and healthcare products, and medical devices. The company offers medicines for various therapeutic areas, including oncology, cardiovascular system, respiratory system, digestive system, and mental diseases. It is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology business. Shenzhen Neptunus Interlong Bio-technique Company Limited was incorporated in 2002 and is based in Quarry Bay, Hong Kong. Shenzhen Neptunus Interlong Bio-technique Company Limited operates as a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Quarry Bay, Hong Kong
- Employees
- 1,321
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.